Clinical Trials Browser

Has results × pertuzumab × 1 year × Clear all

NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Terminated

190 enrolled 13 charts

Breast Neoplasms

NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Phase 2 Active not recruiting

35 enrolled 10 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled 10 charts

Prostatic Neoplasms

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Phase 2 Active not recruiting

19 enrolled 26 charts

HER2-positive Metastatic Breast Cancer

NCT03820141 2026-04-20

DTP

Phase 2 Active not recruiting

51 enrolled 12 charts

Breast Neoplasms

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2 Active not recruiting

164 enrolled 19 charts

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

240 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Phase 2 Completed

23 enrolled 10 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT05954143 2025-11-20

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 13 charts

Breast Neoplasms

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT04425018 2025-11-18

MARGOT

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast Neoplasms

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase 2 Active not recruiting

18 enrolled 8 charts

Breast Neoplasms

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Phase 1/2 Terminated

2 enrolled 6 charts

Breast Neoplasms

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 3 Completed

315 enrolled 11 charts

Breast Neoplasms

NCT01937117 2025-07-01

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Phase 2 Active not recruiting

88 enrolled 15 charts

Breast Neoplasms

NCT03747120 2025-06-27

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

Phase 2 Active not recruiting

138 enrolled 14 charts

Breast Neoplasms